Moss, 29 August 2024
Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests, today announced its results for the second quarter 2024.
Highlights
- Sales of NOK 38.3 million in 2Q24, up 12% vs 2Q23 (13% organic growth). Revenue of NOK 76.8 million in 1H24 up 17% vs 1H23 (16% organic growth).
- EBITDA of NOK 6.8 million in 2Q24 versus NOK 3.6 million in 2Q23. EBITDA of NOK 11.6 million in 1H24 versus NOK 3.1 million in 1H23.
- Gross margin of 57% positively influenced by favourable product mix and finalisation of integration with Getica AB, which was acquired in July 2023
- Sales of fCAL® turbo increased 26% in 2Q24 compared to 2Q23 and by 33% in 1H24 vs 1H23.
- Sales of Cystatin C were NOK 13.3 million during 2Q24 and NOK 28.2 million in 1H24 recording growth of 8% and 9% respectively. Weakened order patterns from China is expected to continue throughout this year.
- Major milestone achieved with the successful completion of NT-proBNP optimisation phase.
GDASA interim report 2Q 2024
GDASA 2Q 24 presentation
Webcast
The company will present the results today at 10.00 am, followed by a Q&A session.
Join the webcast and submit questions via the following link: https://attendee.gotowebinar.com/register/759916907804036701
The webcast will be available on the company website after the presentation.
IR contact:
Njaal Kind, CEO
njaal.kind@gentian.no
+47 919 06 525 (mobile)
This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act. This stock exchange announcement was published by Ole Sørlie, Business Controller at Gentian Diagnostics ASA, on 29 August 2024 at 08:00 CET.
About Gentian
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within homogenous immunoassays, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian is headquartered in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA, and China. For more information, please visit www.gentian.com.